We are live on ! Find out more
SFCM

Seven Fleet Capital Management Portfolio holdings

AUM $318M
This Fund
S&P 500
This Quarter Est. Return
+21.73%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$318M
AUM Growth
+$170M
Cap. Flow
+$133M
Cap. Flow %
41.89%
Top 10 Hldgs %
51.26%
Holding
144
New
59
Increased
36
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
IPSC icon
Century Therapeutics
IPSC
+$6.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$5.04M
3
PCVX icon
Vaxcyte
PCVX
+$4.51M
4
TNGX icon
Tango Therapeutics
TNGX
+$3.99M
5
TYRA icon
Tyra Biosciences
TYRA
+$3.76M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$81.6M
2
TERN
Terns Pharmaceuticals
TERN
+$5.27M
3
EXEL icon
Exelixis
EXEL
+$3.01M
4
COGT icon
Cogent Biosciences
COGT
+$2.39M
5
BLTE
Belite Bio
BLTE
+$1.47M

Sector Composition

Rank Sector Weight
1 Healthcare 55.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLYM
51
Climb Bio
CLYM
$868M
$895K 0.28%
130,654
+54,254
+71% +$313K
CMPS
52
Compass Pathways
CMPS
$1.9B
$874K 0.27%
158,021
+118,021
+295% +$794K
ALKS icon
53
Alkermes
ALKS
$8.36B
$855K 0.27%
+24,170
New +$750K
SLN
54
Silence Therapeutics
SLN
$666M
$826K 0.26%
156,759
+9,159
+6% +$50.4K
CRBP icon
55
Corbus Pharmaceuticals
CRBP
$191M
$805K 0.25%
85,687
+28,937
+51% +$244K
CELC icon
56
Celcuity
CELC
$4.39B
$685K 0.22%
6,000
-2,338
-28% -$255K
ANTX icon
57
AN2 Therapeutics
ANTX
$232M
$683K 0.21%
+199,701
New +$412K
DNLI icon
58
Denali Therapeutics
DNLI
$4.04B
$677K 0.21%
+35,286
New +$702K
UTHR icon
59
United Therapeutics
UTHR
$21.7B
$669K 0.21%
1,128
-172
-13% -$85.7K
LLY icon
60
Eli Lilly
LLY
$1.09T
$662K 0.21%
+720
New +$730K
VSTM icon
61
Verastem
VSTM
$627M
$654K 0.21%
123,400
+108,260
+715% +$668K
GERN icon
62
Geron
GERN
$1.01B
$632K 0.2%
424,180
-353,700
-45% -$538K
IRD
63
Opus Genetics
IRD
$317M
$611K 0.19%
+134,242
New +$464K
IKT icon
64
Inhibikase Therapeutics
IKT
$378M
$547K 0.17%
325,600
-208,048
-39% -$369K
CNTX icon
65
Context Therapeutics
CNTX
$43.2M
$500K 0.16%
+190,785
New +$446K
DRUG
66
Bright Minds Biosciences
DRUG
$768M
$467K 0.15%
+6,395
New +$515K
VYGR icon
67
Voyager Therapeutics
VYGR
$199M
$445K 0.14%
+115,203
New +$454K
GPCR icon
68
Structure Therapeutics
GPCR
$3.78B
$434K 0.14%
+9,000
New +$616K
PTGX icon
69
Protagonist Therapeutics
PTGX
$9.95B
$422K 0.13%
4,000
-4,000
-50% -$354K
PRTA icon
70
Prothena Corp
PRTA
$478M
$421K 0.13%
43,300
– –
NTLA icon
71
Intellia Therapeutics
NTLA
$1.68B
$404K 0.13%
+31,500
New +$401K
MIST icon
72
Milestone Pharmaceuticals
MIST
$137M
$397K 0.12%
+333,333
New +$584K
SABS icon
73
SAB Biotherapeutics
SABS
$347M
$383K 0.12%
+100,000
New +$399K
PALI icon
74
Palisade Bio
PALI
$362M
$373K 0.12%
213,100
-114,400
-35% -$208K
GLUE icon
75
Monte Rosa Therapeutics
GLUE
$1.38B
$371K 0.12%
22,530
+18,530
+463% +$354K
1 2
3
4 5

Similar funds

SA
SAM Advisors Oakhurst, California $319M AUM 17.08% 1-Year Est. Return
KI
Keewaydin Investments Southampton, New York $317M AUM
CPH
C Partners Holding Zurich, Switzerland $317M AUM 4.76% 1-Year Est. Return
FNWM
Financial Network Wealth Management Draper, Utah $316M AUM
MJFG
Mars Jewett Financial Group Bellevue, Washington $316M AUM
KC
KHIS Custodian Dallas, Texas $316M AUM
EC
Edenbrook Capital Mt. Kisco, New York $321M AUM 79.21% 1-Year Est. Return
WA
Waterford Advisors Orchard Park, New York $315M AUM 15.21% 1-Year Est. Return

Seven Fleet Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Seven Fleet Capital Management held 144 positions worth $318M, up 115% from $148M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Seven Fleet Capital Management deployed $133M of net new capital in Q1 2026, opening 59 new positions and adding to 36 existing holdings. Its largest new stake was Century Therapeutics: 2,947,826 shares worth $6.66M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was CG Oncology, an estimated $81.6M trimmed.

  • Seven Fleet Capital Management's largest Q1 2026 buy was Century Therapeutics: 2,947,826 shares worth $6.66M.
  • Seven Fleet Capital Management added most to Agios Pharmaceuticals in Q1 2026, an estimated $5.04M increase.
  • Seven Fleet Capital Management's biggest Q1 2026 reduction was CG Oncology, cutting an estimated $81.6M.
  • Seven Fleet Capital Management fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $5.27M.
  • Seven Fleet Capital Management's ten largest holdings make up 51% of its $318M portfolio in Q1 2026.
  • Seven Fleet Capital Management opened 59 new positions and closed 29 in Q1 2026.
  • Seven Fleet Capital Management's portfolio value rose 115% quarter-over-quarter to $318M.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.